Core Insights - The pet economy in China is rapidly expanding, with the market expected to exceed 811.4 billion yuan by 2025, and the urban pet population reaching 120 million [2][6]. Group 1: Industry Overview - The pet economy has evolved from mere companionship to a lifestyle, creating a vast ecosystem around the entire lifecycle of pets [5][6]. - The geographical distribution and specialization within the pet industry have developed into a national framework, with significant contributions from various regions [6][7]. Group 2: Regional Highlights - Liaoning Anshan is emerging as a major hub for pet breeding, supplying over 60% of the national pet dog and cat population, with an industry scale exceeding 10 billion yuan [18][19][20]. - Hebei and Shandong are recognized as the primary pet food production areas, with a projected 14% increase in pet food shipment volume by 2025 [30][31]. - The Yangtze River Delta is positioned as the "universe center" for pet supplies, leveraging its supply chain advantages and manufacturing capabilities [49][50]. Group 3: Emerging Trends - The pet vaccine sector is witnessing significant growth, with companies like Princely and Jinhe Bio reporting substantial revenue increases, indicating a burgeoning market for pet health products [78][86]. - The smart pet products market is projected to surpass 10.2 billion yuan, driven by advancements in AI and e-commerce integration [91][92]. - The "pet+" trend is gaining traction, with services like pet transportation and photography experiencing exponential growth, reflecting a shift towards emotional spending in pet ownership [106][108]. Group 4: Infrastructure and Services - Guangzhou Baiyun Airport has become the first pet-friendly airport in China, facilitating easier travel for pet owners [120][129]. - The development of pet-friendly cities and services is on the rise, enhancing the overall experience for pet owners and their pets [116][118].

每经AI快讯，普莱柯1月20日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润为 1.76亿元~1.95亿元，与上年同期相比，增加8319.35万元~1.02亿元，同比上升89.64%~110.11%。业绩变 动主要原因是，报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过 持续发力渠道搭建和品牌打造进而取得了快速发展。2025年，面对行业竞争加剧、价格承压以及下游养 殖行情波动等不利因素，公司聚焦营销体系变革，加强销售费用管控，同时优化生产工艺和采购管理， 进一步降低生产成本，整体展现了较强的经营韧性，实现了高质量、高效益发展的经营目标。 （记者 曾健辉） 每经头条（nbdtoutiao）——"一周干完一年的活"，一款AI编程工具让硅谷程序员集体"上瘾"！科技公 司CEO：一辈子钻研的技能被它一次性解决，让人兴奋又恐惧 ...

人民财讯1月20日电，普莱柯（603566）1月20日公告，预计2025年年度实现归属于母公司所有者的净利 润为1.76亿元到1.95亿元，同比上升89.64%到110.11%。报告期，禽腺病毒系列联苗等新产品上市为公 司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭建和品牌打造进而取得了快速发展。 ...

普莱柯（603566）(603566.SH)披露2025年年度业绩预告，公司预计2025年年度实现归属于母公司所有 者的净利润为1.76亿元到1.95亿元，同比上升89.64%到110.11%;实现归属于母公司所有者的扣除非经常 性损益的净利润为1.37亿元到1.53亿元，同比上升70.19%到90.07%。 报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭 建和品牌打造进而取得了快速发展。 ...

证券代码：603566 证券简称：普莱柯 公告编号：2026-004 普莱柯生物工程股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 一、本期业绩预告情况 （一）本期业绩预告期间 三、本期业绩预增的主要原因 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告具体情况 1、经公司财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的 净利润为 17,600.00 万元到 19,500.00 万元，与上年同期相比，增加 8,319.35 万元 到 10,219.35 万元，同比上升 89.64%到 110.11%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润为 13,700.00 万元到 15,300.00 万元，与上年同期相比，增加 5,650.30 万元到 7,250.30 万元，同比上升 70.19%到 90.07%。 2、本次业绩预告为公司初步测算数据，未经审计。 二、上年同期经营业绩和财务状况 （一）归属 ...

智通财经APP讯，普莱柯(603566.SH)披露2025年年度业绩预告，公司预计2025年年度实现归属于母公 司所有者的净利润为1.76亿元到1.95亿元，同比上升89.64%到110.11%;实现归属于母公司所有者的扣除 非经常性损益的净利润为1.37亿元到1.53亿元，同比上升70.19%到90.07%。 报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭 建和品牌打造进而取得了快速发展。 ...

格隆汇1月20日丨普莱柯(603566.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母公 司所有者的净利润为17,600.00万元到19,500.00万元，同比上升89.64%到110.11%。预计2025年年度实现 归属于母公司所有者的扣除非经常性损益的净利润为13,700.00万元到15,300.00万元，同比上升70.19% 到90.07%。 报告期，禽腺病毒系列联苗等新产品上市为公司贡献了新的业绩增长点，宠物板块通过持续发力渠道搭 建和品牌打造进而取得了快速发展。2025年，面对行业竞争加剧、价格承压以及下游养殖行情波动等不 利因素，公司聚焦营销体系变革，加强销售费用管控，同时优化生产工艺和采购管理，进一步降低生产 成本，整体展现了较强的经营韧性，实现了高质量、高效益发展的经营目标。 ...

普莱柯公告称，预计2025年年度实现归属于母公司所有者的净利润1.76亿元到1.95亿元，同比上升 89.64%到110.11%；扣非净利润1.37亿元到1.53亿元，同比上升70.19%到90.07%。上年同期，公司归母 净利润9280.65万元，扣非净利润8049.70万元。业绩预增主要因禽腺病毒系列联苗等新产品上市，宠物 板块发展良好，且公司聚焦营销变革、降本增效。本次业绩预告为初步测算数据，未经审计。 ...

Market Overview - The animal health sector increased by 3.21% on January 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] Stock Performance - Huisheng Biological (300871) closed at 28.16, up 8.18% with a trading volume of 331,800 shares [1] - Zhongmu Co., Ltd. (600195) closed at 8.49, up 7.88% with a trading volume of 435,600 shares [1] - Other notable performers include: - Biological Co. (600201) at 18.28, up 3.80% [1] - Jinhai Biological (002688) at 6.45, up 3.53% [1] - Shunlian Biological (688098) at 9.91, up 3.23% [1] Capital Flow - The animal health sector saw a net inflow of 175 million yuan from institutional investors, while retail investors experienced a net outflow of 171 million yuan [2] - The main capital flow details include: - Huisheng Biological had a net outflow of 59.49 million yuan from institutional investors [3] - Biological Co. had a net inflow of 58.13 million yuan from institutional investors [3] - Jinhai Biological experienced a net inflow of 35.35 million yuan from institutional investors [3]

Group 1 - The core viewpoint of the article highlights the significant role of AI technology in enhancing the efficiency of key processes in the development of gene-engineered vaccines, such as structural prediction of recombinant proteins, antigen screening, and expression [2] Group 2 - The company, Pulaike, responded to investor inquiries on an interactive platform, emphasizing the importance of AI in vaccine research and development [2]